Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery–jugular vein shunt pulmonary hypertension rat model-Reference-Cited by-同舟云学术

Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery–jugular vein shunt pulmonary hypertension rat model

Published:2017-05-04 Issue:2 Volume:25 Page:206-211
ISSN:1569-9293
Container-title:Interactive CardioVascular and Thoracic Surgery
language:en
Short-container-title:

Author:

Ma Xiaofan¹,Yao Jianping¹,Yue Yuan¹,Du Shangming¹,Qin Han¹,Hou Jian¹,Wu Zhongkai¹

Affiliation:

1. Department of Paediatric and Congenital Cardiac Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Funder

National Natural Science Foundation of China

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Link

http://academic.oup.com/icvts/article-pdf/25/2/206/19913660/ivx053.pdf

Reference21 articles.

1. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy;Dimopoulos;Int J Cardiol,2008

2. Pharmacological targets for pulmonary vascular disease: vasodilation versus anti-remodelling;Thomas;Adv Exp Med Biol,2010

3. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome;Galie;Drugs,2008

4. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease;Gatzoulis;Eur Respir Rev,2009

5. Cellular and molecular basis of pulmonary arterial hypertension;Morrell;J Am Coll Cardiol,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Soluble TGF-β Factors;JACC: Basic to Translational Science;2024-06

2. Disruption of DLL4/NOTCH1 Causes Dysregulated PPARγ/AKT Signaling in Pulmonary Arterial Hypertension;2024-02-02

3. Mammalian Target of Rapamycin as the Therapeutic Target of Vascular Proliferative Diseases: Past, Present, and Future;Journal of Cardiovascular Pharmacology;2022-04

4. The therapeutic effect and mechanism of Rapamycin combined with HO-3867 on monocrotaline-induced pulmonary hypertension in rats;European Journal of Pharmaceutical Sciences;2022-03

5. Thioredoxin system activation is associated with the progression of experimental pulmonary arterial hypertension;Life Sciences;2021-11